Level C· Early human research exploring benefitsProspective StudyPubMed

In vitro testing of immunosupressive effects of mesenchymal stromal cells on lymphocytes stimulated with alloantigens.

Lysak D., Vlas T., Holubova M., Miklikova M., Jindra P.

Prospective Study on Immune Modulation, published in Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2013) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2013)
Country
Czech Republic
Reported sample size
—
Source database
PubMed
PMID
24077235
DOI
10.5507/bp.2013.072

Abstract (original English)

Mesenchymal stromal cells (MSC) derived from adult bone marrow or adipose tissue offer the potential to open a new frontier in medicine. MSC are involved in modulating immune response and tissue repair in vitro and in vivo. Experimental evidence and preliminary clinical studies have demonstrated that MSC exhibit an important immunomodulatory function in patients with graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. The immunosuppressive properties of MSC have already been exploited in the clinical setting. However the precise mechanisms are being still investigated. We examined the immunosuppressive function of MSC by coculturing them with stimulated HLA incompatible allogeneic lymphocytes in a mixed lymphocyte culture test. The metabolic and proliferative activity of lymphocytes was determined by MTT test. After stimulation with alloantigens the presence of MSC caused significant decrease of absorbance levels by 62% (P<0.01), 26% (P<0.01) and 6% (P=0.0437) in comparison to positive control depending on the MSC/lymphocyte ratio (1:5, 1:50, 1:500). The mitogenic stimulation of lymphocytes with fMLP or PHA was also significantly reduced during MSC cocultivation. The absorbance was reduced by 42% (P<0.001) and 67% (P<0.001). Allogeneic bone marrow is an ideal source of MSC for clinical application. The experiments confirmed the dose-de

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdultCell ProliferationCells, CulturedGraft vs Host DiseaseHLA AntigensHumansImmune ToleranceIn Vitro TechniquesIsoantigensLymphocytes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research